Back to List View Graph View

TP53

TP53 is a protein-coding gene that encodes the tumor suppressor protein p53, a central regulator of cellular responses to stress, including DNA damage, oncogenic signaling, oxidative stress, and abnormal proliferative signals.

Where the papers sit

59 papers from the last 6 months study TP53 directly · updated from PubMed 16 Nov 2026

  • Breast Cancer Drug Discovery

    Breast cancer drug discovery is moving from broad compound screening toward p53 restoration, ferroptosis modulation, and targeted delivery. Molecular docking and multi-omics repeatedly nominate compounds affecting EGFR, ROS, or mutant p53. Doxorubicin resistance remains linked to p53 suppression of HIF-1α/TFRC-mediated ferroptosis, while trastuzumab-associated ferroptosis offers a contrasting therapeutic signal. Validation remains early, relying on organoids, in vitro assays, and computational prioritization.

    17 papers · 28.8%

  • p53-Linked Cellular Stress

    p53-linked cellular stress connects senescence, apoptosis, metabolic injury, and impaired tissue repair across cancer, diabetes, ischemia, and inflammatory disease. Recurrent mechanisms include PTEN/AKT/p53 signaling, JNK-driven β-cell death, RUNX1–p53 control of macrophage senescence, and HDAC-dependent p53 regulation. Biomaterials, small molecules, and engineered patches aim to alter these pathways or restore damaged tissues. The work remains mechanistically broad, with no single intervention or disease endpoint dominating.

    14 papers · 23.7%

  • Cancer Signaling and Molecular Stratification

    Molecular stratification is being paired with pathway-directed treatment across solid tumors, while transcriptional and post-transcriptional control remains central. MDM2 degradation, mutant p53 repression of SPP1, YTHDF1–SETD2 regulation, and GDOWN1-mediated transcriptional termination nominate therapeutic vulnerabilities. Biomarker panels incorporating FGFR3, KRAS, HRAS, and TP53 modestly improve prognostic prediction beyond TNM staging. The cluster also includes endometrial disease and tissue-injury studies, so clinical translation remains broader than any single pathway.

    12 papers · 20.3%

  • p53-Mediated Apoptosis

    Apoptosis-inducing compounds are being developed around the p53–BCL2/BAX–caspase axis rather than nonspecific cytotoxicity alone. ROS-mediated p53 activation, Akt/MDM2 suppression, and GSK3β-linked signaling recur across flavonoids, metal complexes, extracts, and synthetic molecules. Doxorubicin studies emphasize CDKN1A and metabolic regulation as determinants of response. Evidence remains mainly cellular and preclinical, leaving selectivity and in vivo efficacy unresolved.

    7 papers · 11.9%

  • TP53-Mutant Acute Myeloid Leukemia

    TP53-mutant AML is driving a search for selective vulnerabilities that spare normal hematopoiesis and overcome venetoclax resistance. CK1α degradation, hypomethylating therapy, and dual MDM2/MDMX inhibition represent complementary attempts to kill leukemia or restore p53 signaling. Allogeneic transplantation studies keep attention on co-mutations and post-transplant outcomes. Pediatric and patient-derived models expand testing, but durable clinical benefit and resistance mechanisms remain open.

    5 papers · 8.5%

  • Others — Genome Editing and Cancer Genetics

    Prime editing is being optimized through extracellular vesicle-like particle delivery and microhomology-mediated replacement of large DNA segments. Separate reports address Li-Fraumeni syndrome with recurrent glioma and chondroblastic osteosarcoma, or model targeted therapy for NRAS-mutant conjunctival melanoma. These topics share cancer genetics only loosely and do not establish a common biological mechanism. The cluster therefore supports technical editing advances alongside isolated cancer case and treatment studies.

    4 papers · 6.8%

PARADIGM SHIFT

p53 activity can promote disease and treatment resistance rather than uniformly protect against damage

The doxorubicin-resistant breast-cancer model and the ER-stress β-cell models of diabetes (PMIDs 42610471, 42544575) overturn the assumption that activating p53 is inherently beneficial. In breast cancer, increased p53 suppresses HIF-1α/TFRC-mediated ferroptosis and promotes doxorubicin resistance, while in stressed human and mouse β cells, a JNK–p53 axis drives apoptosis and diabetes-associated cell loss. The therapeutic consequence is that p53 restoration or activation cannot be treated as universally protective; in these settings, selectively inhibiting p53-linked signaling may instead improve chemotherapy response or preserve tissue.

Papers

The 59 papers from the last 6 months that study TP53 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Breast Cancer Drug Discovery (17)
  1. In silico prioritization with preliminary in vitro assessment of UV-328-associated molecular responses in colorectal cancer cells. Functional & integrative genomics · 5 Nov 2026 PMID 42986495
  2. scHGNN: A single-cell gene regulatory network inference method based on heuristic graph neural networks. Functional & integrative genomics · 23 Oct 2026 PMID 42918896
  3. Restoration of p53 function via hybrid strontium sulfite nanoparticles modified LNP improves the antitumor efficacy in breast cancers. Cancer gene therapy · 15 Oct 2026 PMID 42881229
  4. Evaluation of Murrayanine's Anticancer Potential in Breast Cancer: Integrative Computational, In Vitro, and Nanoparticle Delivery Approaches. The Journal of steroid biochemistry and molecular biology · 14 Oct 2026 PMID 42874789
  5. Exploring the cytotoxic potential of Artemisia herba-alba crude extract and key phytoconstituents using in vitro assays and molecular docking insights. PloS one · 25 Sept 2026 PMID 42789608
  6. Covalent Targeting and Thermostabilization of Oncogenic R280K and R273H Mutants p53 by Small Molecule RVJB59. ChemMedChem · 5 Sept 2026 PMID 42701099
  7. Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids. Cancer chemotherapy and pharmacology · 2 Sept 2026 PMID 42684430
  8. Integrated multi-omics, machine learning, network toxicology, and molecular docking reveal potential mechanisms underlying methyl 4-hydroxybenzoate-associated breast cancer. Molecular diversity · 28 Aug 2026 PMID 42665765
  9. Phycocyanobilin: A potential bioactive compound from Arthrospira platensis targeting LYN protein associated with systemic lupus erythematosus. PloS one · 28 Aug 2026 PMID 42664210
  10. The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) · 27 Aug 2026 PMID 42660014
  11. P53 Competitively Binds P300 to Suppress HIF-1α/TFRC-Mediated Ferroptosis and Promote Doxorubicin Resistance in Breast Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 18 Aug 2026 PMID 42610471
  12. Network pharmacology and molecular simulation study on the multi-target gene regulatory mechanism of Isatis indigotica against hepatic inflammation. PloS one · 13 Aug 2026 PMID 42594138
  13. WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers. Oncotarget · 21 Jul 2026 PMID 42478852
  14. Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment · 20 Jul 2026 PMID 42474755
  15. Computational design and experimental validation of peptide inhibitors targeting the p53-COP1 interaction to suppress p53 ubiquitination. Bioorganic chemistry · 3 Jul 2026 PMID 42398393
  16. Spatial biomarker discovery via interpretable semantic learning in histopathology. Cancer cell · 11 Jun 2026 PMID 42276049
  17. Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes. The Journal of clinical investigation · 9 Jun 2026 PMID 42262879
p53-Linked Cellular Stress (14)
  1. TP53 dysregulation in Wilms tumor: an integrative clinico-genomic analysis and its prognostic implications. Molecular genetics and genomics : MGG · 30 Oct 2026 PMID 42961508
  2. Sensitive fluorescent biosensors based on a cascade signal amplification strategy and a stimuli-responsive hydrogel for the detection of the p53 gene. The Analyst · 29 Sept 2026 PMID 42808805
  3. A PIWI-interacting RNA-loaded gelatin methacryloyl microneedle patch improves wound repair following cutaneous injury. European journal of pharmacology · 12 Aug 2026 PMID 42586253
  4. JTE-013 ameliorates allergic asthma by targeting the S1PR2-HDAC3-p53 signaling axis to improve mitochondrial homeostasis. International immunopharmacology · 10 Aug 2026 PMID 42574803
  5. JNK and p53 cause human and mouse β cell death during excessive unfolded protein response. The Journal of clinical investigation · 3 Aug 2026 PMID 42544575
  6. Stepwise malignant transformation from MHL to UESL via activation of C19MC and loss of TP53. NPJ precision oncology · 14 Jul 2026 PMID 42448860
  7. Radiobiological effects of flattening filter and flattening filter free radiotherapy x-ray on inflammatory and apoptotic pathways in cardiac and pulmonary tissues in an MCF-7 xenograft breast cancer model. Journal of radiation research · 7 Jul 2026 PMID 42411639
  8. Multi-omics integration identifies macrophage senescence driven by the RUNX1-P53 axis as a key mechanism in diabetic foot ulcer. Functional & integrative genomics · 3 Jul 2026 PMID 42399485
  9. CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway. Human cell · 1 Jul 2026 PMID 42384246
  10. Development and Biological Evaluation of a GLUT-Inhibiting Theranostic Agent, MF48, for Colorectal Cancer Therapy. ACS applied bio materials · 18 Jun 2026 PMID 42315971
  11. 3D-printed PCL/nHA/SA/COL loaded with M2 macrophage-derived exosomes alleviates the senescence of bone marrow mesenchymal stem cells. International immunopharmacology · 11 Jun 2026 PMID 42275920
  12. Unveiling the Potential Therapeutic Efficacy of Gold Ceria Nanohybrid as an Anticancer Agent: A Special Insight to Molecular Docking Study. ACS applied bio materials · 4 Jun 2026 PMID 42240071
  13. [Expression of Concern] Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. International journal of oncology · 22 May 2026 PMID 42169657
  14. In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity. Journal of enzyme inhibition and medicinal chemistry · 21 May 2026 PMID 42163716
Cancer Signaling and Molecular Stratification (12)
  1. An Accessible Approach to Molecular and Biomarker Testing for Risk Stratification in Oral Cavity Squamous Cell Carcinoma. Head and neck pathology · 18 Sept 2026 PMID 42758366
  2. DHCR24 promotes endometrial carcinoma progression and is associated with cellular senescence regulation. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742784
  3. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  4. Exosomal miR-22-3p targets p53 to regulate endometrial epithelial cell function in the pathogenesis of endometriosis. Journal of molecular histology · 4 Sept 2026 PMID 42693330
  5. Targeting the PARP1-p53 Axis Could Mitigate Necrotic-Apoptotic Signaling and Secondary Neurodegeneration After Spinal Cord Injury. Molecular neurobiology · 28 Aug 2026 PMID 42665756
  6. Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. International journal of urology : official journal of the Japanese Urological Association · 27 Aug 2026 PMID 42655970
  7. Nuclear-targeted GDOWN1 potently suppresses tumors by inducing premature transcription termination and exporting Pol Ⅱ CTD phosphatases to activate RB. Cell death and differentiation · 26 Aug 2026 PMID 42649379
  8. YTHDF1-mediated translational activation of SETD2 suppresses aerobic glycolysis and sensitizes renal cell carcinoma to sunitinib. Cellular signalling · 26 Aug 2026 PMID 42648585
  9. Proteo-genomics-guided interpretation of somatic mutations in cancer genomes. Cancer cell · 21 Aug 2026 PMID 42628524
  10. MTA does not induce oxidative stress and apoptotic response, or calcium-related cellular stress and preserves extracellular matrix homeostasis. Molecular biology reports · 24 Jul 2026 PMID 42496770
  11. Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models. The Journal of clinical investigation · 1 Jul 2026 PMID 42383359
  12. Mechanism of toxicity of TiO2 nanoparticles exposure on restraining bone growth of young rats: acting on HDAC9 nucleocytoplasmic translocation-mediated p53 deacetylation involving in growth plate chondrocyte differentiation and ferroptosis. Chemico-biological interactions · 29 May 2026 PMID 42214481
p53-Mediated Apoptosis (7)
  1. Integrated Multi-omics Reveals CDKN1A Suppression and Metabolic Regulation as Key Mechanisms of Huangqi Guizhi Wuwu Decoction Against Doxorubicin-Induced Cardiotoxicity. Cardiovascular toxicology · 21 Aug 2026 PMID 42627580
  2. Brown Adipose Tissue Activation Alleviates Cerebral Ischemia-Reperfusion Injury by Increasing 14-3-3ζ Secretion from Circulating Extracellular Vesicles to Suppress P53 Activity. Molecular neurobiology · 22 Jul 2026 PMID 42484740
  3. Synthesis, in vitro and in silico studies of transition metal complexes of chrysin with potent anticancer activity via GSK3β phosphorylation, modulation of p38 MAPK pathway and HDAC8 inhibition. Bioorganic chemistry · 17 Jul 2026 PMID 42468084
  4. 4-Chloro-7-Nitrobenzofurazan induces ROS-mediated p53 dependent apoptosis in human fibrosarcoma cells. Molecular biology reports · 10 Jul 2026 PMID 42429843
  5. Silver-loaded nanoemulsion of Nepeta glomerulosa extract enhances cytotoxicity and induces apoptosis in A549 and AGS cancer cells. Journal of the Egyptian National Cancer Institute · 6 Jul 2026 PMID 42406222
  6. Prenylated flavonoids from Sophora flavescens (Kushen) inhibit hepatocellular carcinoma growth by suppressing the Akt/MDM2/p53 pathway to activate mitochondrial apoptosis. Phytomedicine : international journal of phytotherapy and phytopharmacology · 29 May 2026 PMID 42214227
  7. Antineoplastic multi-targeted spiro[indoline-3,2'-pyrrolidines] incorporating urea function: Rational design, synthesis and bio-properties studies. Bioorganic chemistry · 27 May 2026 PMID 42202589
TP53-Mutant Acute Myeloid Leukemia (5)
  1. A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells. Cancer research · 3 Aug 2026 PMID 42545171
  2. The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42439804
  3. Impact of concurrent genetic alterations on outcomes after allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes. Cancer letters · 10 Jul 2026 PMID 42431390
  4. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia · 1 Jul 2026 PMID 42380664
  5. A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189874
Others — Genome Editing and Cancer Genetics (4)
  1. Li-Fraumeni syndrome presenting with temporomandibular chondroblastic osteosarcoma following recurrent glioma. BMJ case reports · 1 Sept 2026 PMID 42680500
  2. Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 31 Jul 2026 PMID 42537395
  3. Compound delivery of eVLPs enhances prime editing for targeted genome engineering and high-throughput screening. Cell genomics · 14 Jul 2026 PMID 42447864
  4. Prime editing-mediated microhomology enables efficient replacement of large DNA. Nucleic acids research · 22 Jun 2026 PMID 42328791

By study type

Clinical trials (1)
  1. A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research · 26 May 2026 PMID 42189874
Observational studies and case reports (5)
  1. Li-Fraumeni syndrome presenting with temporomandibular chondroblastic osteosarcoma following recurrent glioma. BMJ case reports · 1 Sept 2026 PMID 42680500
  2. Integrating Molecular Classification Based on FGFR3, KRAS, HRAS, and TP53 Mutation With TNM Staging Modestly Improves Prediction of Prognosis of Upper Tract Urothelial Carcinoma After Surgery. International journal of urology : official journal of the Japanese Urological Association · 27 Aug 2026 PMID 42655970
  3. WIN-MTB-2024017 - WIN International Molecular Tumor Board: A 48-year-old female with multiple primary cancers. Oncotarget · 21 Jul 2026 PMID 42478852
  4. Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment · 20 Jul 2026 PMID 42474755
  5. Impact of concurrent genetic alterations on outcomes after allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes. Cancer letters · 10 Jul 2026 PMID 42431390
Human data, design not indexed (14)
  1. TP53 dysregulation in Wilms tumor: an integrative clinico-genomic analysis and its prognostic implications. Molecular genetics and genomics : MGG · 30 Oct 2026 PMID 42961508
  2. scHGNN: A single-cell gene regulatory network inference method based on heuristic graph neural networks. Functional & integrative genomics · 23 Oct 2026 PMID 42918896
  3. Sensitive fluorescent biosensors based on a cascade signal amplification strategy and a stimuli-responsive hydrogel for the detection of the p53 gene. The Analyst · 29 Sept 2026 PMID 42808805
  4. An Accessible Approach to Molecular and Biomarker Testing for Risk Stratification in Oral Cavity Squamous Cell Carcinoma. Head and neck pathology · 18 Sept 2026 PMID 42758366
  5. Covalent Targeting and Thermostabilization of Oncogenic R280K and R273H Mutants p53 by Small Molecule RVJB59. ChemMedChem · 5 Sept 2026 PMID 42701099
  6. Phycocyanobilin: A potential bioactive compound from Arthrospira platensis targeting LYN protein associated with systemic lupus erythematosus. PloS one · 28 Aug 2026 PMID 42664210
  7. The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC). Lung cancer (Amsterdam, Netherlands) · 27 Aug 2026 PMID 42660014
  8. Proteo-genomics-guided interpretation of somatic mutations in cancer genomes. Cancer cell · 21 Aug 2026 PMID 42628524
  9. Network pharmacology and molecular simulation study on the multi-target gene regulatory mechanism of Isatis indigotica against hepatic inflammation. PloS one · 13 Aug 2026 PMID 42594138
  10. Multi-omics integration identifies macrophage senescence driven by the RUNX1-P53 axis as a key mechanism in diabetic foot ulcer. Functional & integrative genomics · 3 Jul 2026 PMID 42399485
  11. Computational design and experimental validation of peptide inhibitors targeting the p53-COP1 interaction to suppress p53 ubiquitination. Bioorganic chemistry · 3 Jul 2026 PMID 42398393
  12. Spatial biomarker discovery via interpretable semantic learning in histopathology. Cancer cell · 11 Jun 2026 PMID 42276049
  13. Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes. The Journal of clinical investigation · 9 Jun 2026 PMID 42262879
  14. [Expression of Concern] Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. International journal of oncology · 22 May 2026 PMID 42169657
Preclinical: animal, cell and lab studies (32)
  1. In silico prioritization with preliminary in vitro assessment of UV-328-associated molecular responses in colorectal cancer cells. Functional & integrative genomics · 5 Nov 2026 PMID 42986495
  2. Exploring the cytotoxic potential of Artemisia herba-alba crude extract and key phytoconstituents using in vitro assays and molecular docking insights. PloS one · 25 Sept 2026 PMID 42789608
  3. DHCR24 promotes endometrial carcinoma progression and is associated with cellular senescence regulation. Medical oncology (Northwood, London, England) · 15 Sept 2026 PMID 42742784
  4. Mutant p53 sensitizes KRAS-driven lung adenocarcinoma to immunotherapy by repressing SPP1. Science advances · 11 Sept 2026 PMID 42726875
  5. Exosomal miR-22-3p targets p53 to regulate endometrial epithelial cell function in the pathogenesis of endometriosis. Journal of molecular histology · 4 Sept 2026 PMID 42693330
  6. Trastuzumab treatment is associated with ferroptosis-related alterations in HER2-positive breast cancer organoids. Cancer chemotherapy and pharmacology · 2 Sept 2026 PMID 42684430
  7. Targeting the PARP1-p53 Axis Could Mitigate Necrotic-Apoptotic Signaling and Secondary Neurodegeneration After Spinal Cord Injury. Molecular neurobiology · 28 Aug 2026 PMID 42665756
  8. Integrated Multi-omics Reveals CDKN1A Suppression and Metabolic Regulation as Key Mechanisms of Huangqi Guizhi Wuwu Decoction Against Doxorubicin-Induced Cardiotoxicity. Cardiovascular toxicology · 21 Aug 2026 PMID 42627580
  9. P53 Competitively Binds P300 to Suppress HIF-1α/TFRC-Mediated Ferroptosis and Promote Doxorubicin Resistance in Breast Cancer. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 18 Aug 2026 PMID 42610471
  10. A PIWI-interacting RNA-loaded gelatin methacryloyl microneedle patch improves wound repair following cutaneous injury. European journal of pharmacology · 12 Aug 2026 PMID 42586253
  11. JTE-013 ameliorates allergic asthma by targeting the S1PR2-HDAC3-p53 signaling axis to improve mitochondrial homeostasis. International immunopharmacology · 10 Aug 2026 PMID 42574803
  12. JNK and p53 cause human and mouse β cell death during excessive unfolded protein response. The Journal of clinical investigation · 3 Aug 2026 PMID 42544575
  13. Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 31 Jul 2026 PMID 42537395
  14. MTA does not induce oxidative stress and apoptotic response, or calcium-related cellular stress and preserves extracellular matrix homeostasis. Molecular biology reports · 24 Jul 2026 PMID 42496770
  15. Brown Adipose Tissue Activation Alleviates Cerebral Ischemia-Reperfusion Injury by Increasing 14-3-3ζ Secretion from Circulating Extracellular Vesicles to Suppress P53 Activity. Molecular neurobiology · 22 Jul 2026 PMID 42484740
  16. Synthesis, in vitro and in silico studies of transition metal complexes of chrysin with potent anticancer activity via GSK3β phosphorylation, modulation of p38 MAPK pathway and HDAC8 inhibition. Bioorganic chemistry · 17 Jul 2026 PMID 42468084
  17. Compound delivery of eVLPs enhances prime editing for targeted genome engineering and high-throughput screening. Cell genomics · 14 Jul 2026 PMID 42447864
  18. The Novel Hypomethylating Agent NTX-301 Reprograms Epigenetic and Hippo Signaling Pathways and Exhibits Preclinical Activity in Venetoclax-Resistant and TP53-Mutant AML. Clinical cancer research : an official journal of the American Association for Cancer Research · 13 Jul 2026 PMID 42439804
  19. 4-Chloro-7-Nitrobenzofurazan induces ROS-mediated p53 dependent apoptosis in human fibrosarcoma cells. Molecular biology reports · 10 Jul 2026 PMID 42429843
  20. Radiobiological effects of flattening filter and flattening filter free radiotherapy x-ray on inflammatory and apoptotic pathways in cardiac and pulmonary tissues in an MCF-7 xenograft breast cancer model. Journal of radiation research · 7 Jul 2026 PMID 42411639
  21. Silver-loaded nanoemulsion of Nepeta glomerulosa extract enhances cytotoxicity and induces apoptosis in A549 and AGS cancer cells. Journal of the Egyptian National Cancer Institute · 6 Jul 2026 PMID 42406222
  22. CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway. Human cell · 1 Jul 2026 PMID 42384246
  23. Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models. The Journal of clinical investigation · 1 Jul 2026 PMID 42383359
  24. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia · 1 Jul 2026 PMID 42380664
  25. Prime editing-mediated microhomology enables efficient replacement of large DNA. Nucleic acids research · 22 Jun 2026 PMID 42328791
  26. Development and Biological Evaluation of a GLUT-Inhibiting Theranostic Agent, MF48, for Colorectal Cancer Therapy. ACS applied bio materials · 18 Jun 2026 PMID 42315971
  27. 3D-printed PCL/nHA/SA/COL loaded with M2 macrophage-derived exosomes alleviates the senescence of bone marrow mesenchymal stem cells. International immunopharmacology · 11 Jun 2026 PMID 42275920
  28. Unveiling the Potential Therapeutic Efficacy of Gold Ceria Nanohybrid as an Anticancer Agent: A Special Insight to Molecular Docking Study. ACS applied bio materials · 4 Jun 2026 PMID 42240071
  29. Mechanism of toxicity of TiO2 nanoparticles exposure on restraining bone growth of young rats: acting on HDAC9 nucleocytoplasmic translocation-mediated p53 deacetylation involving in growth plate chondrocyte differentiation and ferroptosis. Chemico-biological interactions · 29 May 2026 PMID 42214481
  30. Prenylated flavonoids from Sophora flavescens (Kushen) inhibit hepatocellular carcinoma growth by suppressing the Akt/MDM2/p53 pathway to activate mitochondrial apoptosis. Phytomedicine : international journal of phytotherapy and phytopharmacology · 29 May 2026 PMID 42214227
  31. Antineoplastic multi-targeted spiro[indoline-3,2'-pyrrolidines] incorporating urea function: Rational design, synthesis and bio-properties studies. Bioorganic chemistry · 27 May 2026 PMID 42202589
  32. In vitro screening of compounds for targeting gastric cancer with Y220C p53 mutation: a molecule combining zinc chelation and a Michael acceptor drives CDKN1 and BBC3 expression to restore a p53-dependent cytotoxicity. Journal of enzyme inhibition and medicinal chemistry · 21 May 2026 PMID 42163716
Unclassified: not yet indexed with MeSH (7)
  1. Restoration of p53 function via hybrid strontium sulfite nanoparticles modified LNP improves the antitumor efficacy in breast cancers. Cancer gene therapy · 15 Oct 2026 PMID 42881229
  2. Evaluation of Murrayanine's Anticancer Potential in Breast Cancer: Integrative Computational, In Vitro, and Nanoparticle Delivery Approaches. The Journal of steroid biochemistry and molecular biology · 14 Oct 2026 PMID 42874789
  3. Integrated multi-omics, machine learning, network toxicology, and molecular docking reveal potential mechanisms underlying methyl 4-hydroxybenzoate-associated breast cancer. Molecular diversity · 28 Aug 2026 PMID 42665765
  4. Nuclear-targeted GDOWN1 potently suppresses tumors by inducing premature transcription termination and exporting Pol Ⅱ CTD phosphatases to activate RB. Cell death and differentiation · 26 Aug 2026 PMID 42649379
  5. YTHDF1-mediated translational activation of SETD2 suppresses aerobic glycolysis and sensitizes renal cell carcinoma to sunitinib. Cellular signalling · 26 Aug 2026 PMID 42648585
  6. A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells. Cancer research · 3 Aug 2026 PMID 42545171
  7. Stepwise malignant transformation from MHL to UESL via activation of C19MC and loss of TP53. NPJ precision oncology · 14 Jul 2026 PMID 42448860